NasdaqGS:RVMDBiotechs
A Look At Revolution Medicines (RVMD) Valuation After FDA Clears Expanded Access To Daraxonrasib
Revolution Medicines (RVMD) is back in focus after the U.S. Food and Drug Administration issued a “safe to proceed” letter for expanded access to its investigational pancreatic cancer therapy, daraxonrasib, for eligible U.S. patients.
See our latest analysis for Revolution Medicines.
The FDA’s expanded access decision comes after a busy period for Revolution Medicines, with the stock’s 30-day share price return of 10.01% and 90-day share price return of 54.05% pointing to strong momentum. The...